Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 17, 2019updated 07 Aug 2019 2:34pm

UNS reports positive results from Alzheimer’s vaccine trial

United Neuroscience (UNS) has reported positive top-line results from its Phase IIa clinical trial evaluating UB-311 in patients with Alzheimer’s disease.

United Neuroscience (UNS) has reported positive top-line results from its Phase IIa clinical trial evaluating UB-311 in patients with Alzheimer’s disease.

The trial met its primary endpoint of safety and immunogenicity with a 96% response rate.

Secondary endpoints of the trial also achieved favourable results, but not statistically significant data among the study patients.

The trial’s secondary endpoints included amyloid PET burden, clinical dementia rating sum of boxes (CDR-SB), Alzheimer’s disease cooperative study activities of daily living inventory (ADCS-ADL) and mini–mental state examination (MMSE).

United Neuroscience research and development executive vice-president Peter Powchik said: “The positive results show that we can safely raise and maintain anti-Aβ antibody titers in a predictable and sustained manner.

“The intent of this Phase IIa study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311.”

“High response rates, reproducibility of response and generation of antibodies directed to relevant toxic protein species are key elements of an effective therapeutic vaccine for neurodegenerative conditions.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“The UNS platform is proving that it can deliver on these requirements.”

UNS’ Phase IIa trial was conducted in a double-blinded, placebo-controlled setting. It examined the safety and immunogenicity of two different dosing regimens of UB-311.

Subjects from the trial will also take part in a long-term extension study and will continue to receive UB-311.

United Neuroscience CEO Mei Mei Hu said: “These early results suggest a clinical response and support the continued and rapid development of UB-311.

“The intent of this Phase IIa study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311 in patients with Alzheimer’s disease.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU